相关实验视频

Updated: Jan 9, 2026

A Novel Feeder-free System for Mass Production of Murine Natural Killer Cells In Vitro

A Novel Feeder-free System for Mass Production of Murine Natural Killer Cells In Vitro

Published on: January 9, 2018

失去EHMT2可以通过抑制TGF-β1增强NK细胞驱动的抗瘤免疫力

Suresh Chava¹, Suresh Bugide¹, Parmanand Malvi¹

¹Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL, 35233, USA.

EMBO molecular medicine

|December 9, 2025

概括

抑制EHMT2通过增强癌细胞消除来提高自然杀手 (NK) 细胞的抗瘤活性. 这一发现揭示了EHMT2作为改善癌症免疫治疗的关键目标.

科学领域:

免疫学免疫学免疫学
癌症生物学癌症生物学
表观遗传学在表观遗传学中,表观遗传学是指表观遗传学.

背景情况:

自然杀手 (NK) 细胞对于瘤监测至关重要,但控制其抗瘤功能的机制尚未完全理解.
鉴定NK细胞介导细胞毒性的调节剂对于开发新型癌症免疫疗法至关重要.

研究的目的:

为了研究基因组甲基转移酶EHMT2在NK细胞介导的抗瘤免疫中的作用.
评估EHMT2抑制作为一种治疗策略,以增强NK细胞对各种癌症的细胞毒性.

主要方法:

使用体外和体外癌症模型研究了EHMT2在NK细胞细胞毒性中的作用.
分析了EHMT2抑制后的分子变化,包括AZGP1,TGF-β1,MICB和ULBP3水平.
利用免疫能力,Rag2淘汰和NSG小鼠模型来评估NK细胞依赖的抗瘤效应.

主要成果:

在癌细胞中抑制EHMT2显著增强了NK细胞介导的乳腺癌,乳腺癌和胰腺癌的消除.
EHMT2的损失导致AZGP1增加和TGF-β1减少,导致NKG2D配体 (MICB,ULBP3) 升高和NK细胞功能增强.
抑制EHMT2抑制了依赖NK细胞的方式抑制瘤,在免疫能力和Rag2淘汰赛小鼠中得到证实.

结论:

EHMT2作为NK细胞介导的抗瘤免疫的抑制剂.
准EHMT2代表了一个有前途的治疗策略,以增强NK细胞的癌症免疫疗法.

关键词:

在AZGP1中,AZGP1是AZGP1.抗瘤免疫力抗瘤免疫力在EHMT2中使用.在 NK 细胞中.在TGF-β1中.

更多相关视频

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.